YL Gu, MA Kampinga, WG Wieringa, ML Fokkema… - Circulation, 2011 - Am Heart Assoc Disclosures None. Youlan L. Gu, MD Marthe A. Kampinga, MD Wouter G. Wieringa, MD Marieke L. Fokkema, BSc Hans L. Hillege, MD, PhD Ad FM van den Heuvel, MD, PhD Eng-Shiong Tan, MD, PhD Gabija Pundziute, MD, PhD Rik van der Werf, MD Siyrous Hoseyni ...
M Ezquer, F Ezquer, M Ricca, C Allers… - Journal of Hepatology, 2011 - Elsevier Metabolic syndrome is secondary to obesity and characterized by dyslipidemia, insulin resistance and hypertension. Non-alcoholic fatty liver disease is its hepatic manifestation, which progression-limiting step is non-alcoholic steatohepatitis (NASH). The latter is typifed by ... All 3 versions
[HTML] from ascopubs.orgE Bardet, L Martin, G Calais, M Alfonsi… - Journal of Clinical …, 2011 - jco.ascopubs.org Patients and Methods Patients with newly diagnosed squamous cell carcinoma of the head and neck, who were eligible for radiotherapy and who were not receiving concurrent chemotherapy, were randomly assigned to receive either IV amifostine (200 mg/m 2 daily ... Cited by 1 - Related articles - All 6 versions
O Honmou, K Houkin, T Matsunaga, Y Niitsu… - Brain, 2011 - Oxford Univ Press Transplantation of human mesenchymal stem cells has been shown to reduce infarct size and improve functional outcome in animal models of stroke. Here, we report a study designed to assess feasibility and safety of transplantation of autologous human mesenchymal stem cells ... Cited by 5 - Related articles - All 5 versions
K Woodburn, C Holmes, KL Fong… - NDT …, 2011 - ndtplus.oxfordjournals.org INTRODUCTION AND AIMS: Hematide™/peginesatide is a PEGylated, investigational, peptide-based erythropoiesis stimulating agent (ESA). It was designed and engineered to stimulate specifically the erythropoietin receptor (EPOr), yet it has no sequence homology to ...